Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05367661 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers
A Phase 1 study, sponsored by Chinook Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT05367661: Clinical Trial Phase 1 study, sponsored by Chinook Therapeutics.
NCT05367661 is a Phase 1 study that was terminated before completion, run by Chinook Therapeutics. The registered enrollment target is 88 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05367661, a Phase 1 study, was terminated before completion, sponsored by Chinook Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
This study is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamic effects of an investigational drug (CHK-336) when administered to healthy volunteers.
Primary Outcome
Incidence, nature, and severity of adverse events (AEs), adverse events of special interest (AESI), and serious adverse events (SAEs)
Interventions
- DRUG Placebo
- DRUG CHK336
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2022-04-08 |
| Est. Completion | 2023-04-19 |
| Phase | Phase 1 |
Why NCT05367661 stopped before completion
NCT05367661 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05367661 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05367661 about?
NCT05367661 is a clinical study titled "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers". This study is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamic effects of an investigational drug (CHK-336) when administered to healthy volunteers.
What is the current status of trial NCT05367661?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2022-04-08. Estimated completion is 2023-04-19.
What interventions are being tested in trial NCT05367661?
The interventions under investigation include: Placebo (DRUG), CHK336 (DRUG).
Who is sponsoring clinical trial NCT05367661?
This trial is sponsored by Chinook Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05367661's enrollment target sits among peer trials
88 650th of 2000 higher than 1,350 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI